Matches in Wikidata for { <http://www.wikidata.org/entity/Q92849020> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q92849020 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92849020 description "im Juni 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92849020 description "scientific article published on 15 June 2019" @default.
- Q92849020 description "wetenschappelijk artikel" @default.
- Q92849020 description "наукова стаття, опублікована 15 червня 2019" @default.
- Q92849020 name "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 name "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 type Item @default.
- Q92849020 label "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 label "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 prefLabel "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 prefLabel "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 P1433 Q92849020-56CE7722-B683-4C49-A042-C4ACFDAF2D9B @default.
- Q92849020 P1476 Q92849020-0FAD2BF0-750A-49C8-A420-D78C12B52E53 @default.
- Q92849020 P2093 Q92849020-188743BC-BBB1-4DC0-84F7-90F9C8A010E2 @default.
- Q92849020 P2093 Q92849020-1DAABA17-03A9-4C56-9D00-03CE9539FE08 @default.
- Q92849020 P2093 Q92849020-1EFE0352-3AC7-4DF7-A7A6-096C5F941221 @default.
- Q92849020 P2093 Q92849020-58866902-2996-42D4-BFB4-5E3066AA966E @default.
- Q92849020 P2093 Q92849020-64DAF99E-7522-408A-8EC7-4AB4E703C13D @default.
- Q92849020 P2093 Q92849020-6E5F9686-9FF3-4FC5-A514-54AAB8F4F13D @default.
- Q92849020 P2093 Q92849020-8CE80A90-830B-4429-B519-DB0B96845DB3 @default.
- Q92849020 P2093 Q92849020-9F367C57-23AA-497B-87F8-3FB96210DE5D @default.
- Q92849020 P2093 Q92849020-A3E5160D-31D1-493C-8B81-14E41DD2712D @default.
- Q92849020 P2093 Q92849020-BC369D7A-BAF0-479E-8083-E852D6C23FE2 @default.
- Q92849020 P2093 Q92849020-C9ABEC2C-820D-405E-894D-8CA366976753 @default.
- Q92849020 P2093 Q92849020-D46A9409-35EE-4794-A54D-0B7F0340B1AA @default.
- Q92849020 P2093 Q92849020-E6730AE9-957B-416A-BAF9-C7FC500EC3CC @default.
- Q92849020 P304 Q92849020-F496C233-BA84-472B-8B72-9C5505B0833F @default.
- Q92849020 P31 Q92849020-C9B67061-7EBD-4B82-9A78-0F82A1D45362 @default.
- Q92849020 P356 Q92849020-08BFA6F2-9DF2-40D4-AA4B-FE5C1FD196D3 @default.
- Q92849020 P433 Q92849020-B5C843AE-814F-48E9-88C8-1B0AC9B92E0E @default.
- Q92849020 P478 Q92849020-1FAC3AF6-A2DD-4F63-AB62-D35975660F10 @default.
- Q92849020 P50 Q92849020-BFB63EBB-EC91-4375-8CA6-C96D6727A90B @default.
- Q92849020 P50 Q92849020-E691D2C2-C660-487D-B7AD-9A64F970EF56 @default.
- Q92849020 P577 Q92849020-79967411-2D9F-43CC-9352-D5A7BD43BCAB @default.
- Q92849020 P698 Q92849020-8C86C922-DB09-410D-A1C9-FFF82B23FA7F @default.
- Q92849020 P921 Q92849020-B4A38550-89FD-4349-AC83-79E8628D1127 @default.
- Q92849020 P932 Q92849020-E155F45D-FBF3-4F92-9A9A-09EAE18C9918 @default.
- Q92849020 P356 J.BBMT.2019.06.007 @default.
- Q92849020 P698 31212080 @default.
- Q92849020 P1433 Q15754328 @default.
- Q92849020 P1476 "A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)" @default.
- Q92849020 P2093 "Frank Beardell" @default.
- Q92849020 P2093 "Jennifer Le-Rademacher" @default.
- Q92849020 P2093 "Kenneth Meehan" @default.
- Q92849020 P2093 "Kouros Owzar" @default.
- Q92849020 P2093 "Kristina Laumann" @default.
- Q92849020 P2093 "Luis Isola" @default.
- Q92849020 P2093 "Margarida DeMagalhaes-Silverman" @default.
- Q92849020 P2093 "Ravi Vij" @default.
- Q92849020 P2093 "Steven Devine" @default.
- Q92849020 P2093 "Sumithira Vasu" @default.
- Q92849020 P2093 "Thomas Shea" @default.
- Q92849020 P2093 "Tsiporah Shore" @default.
- Q92849020 P2093 "Vera Hars" @default.
- Q92849020 P304 "1984-1992" @default.
- Q92849020 P31 Q13442814 @default.
- Q92849020 P356 "10.1016/J.BBMT.2019.06.007" @default.
- Q92849020 P433 "10" @default.
- Q92849020 P478 "25" @default.
- Q92849020 P50 Q115538665 @default.
- Q92849020 P50 Q89209246 @default.
- Q92849020 P577 "2019-06-15T00:00:00Z" @default.
- Q92849020 P698 "31212080" @default.
- Q92849020 P921 Q264118 @default.
- Q92849020 P932 "6790289" @default.